Pigmentary Disorders

At the SDPA 2022 Annual Summer Dermatology Conference, a session on both common and rare dermatological disorders.

Ruxolitinib cream 1.5% may soon be the first FDA-approved treatment for repigmentation of vitiligo. Experts share what dermatologists need to know regarding efficacy, safety, and cost of this topical drug.

The skincare manufacturer and distributer announced that it has received patents for hair growth and melasma.

VisualDX uses diverse imagery to help increase knowledge of disease manifestations in a range of skin types.

In a presentation at the current AAD annual meeting, experts discussed differential diagnoses and clinical presentations in birthmarks and hamartomas.

Investigator Loren Krueger, MD, urges dermatologists to recognize and correct disparities in clinical decision-making, particularly regarding skin cancer.

Unsafe and toxic skin-whitening products continue to draw fire.

Suneel Chilukuri, MD, discusses new innovations in dermatology, including hyperpigmentation, in his presentation at the Maui Derm for Dermatologists meeting.

Hyperpigmentation requires dermatologists to take a multimodal approach and be familiar with a menu of treatments, according to a presentation given at Maui Derm for Dermatologists 2022, held January 24 to 28, 2022 in Maui Hawaii, and virtual.

The Skin of Color Society released an article detailing its 2021 achievements, containing what the society considers its most active and successful year.